GNA Biosolutions named finalist for AACC’s Inaugural Disruptive Technology Award

On July 30, 2018, GNA Biosolutions will be one of three finalists in the American Association of Clinical Chemistry’s (AACC) first-ever Disruptive Technology Award. GNA will be presenting data on the company’s proprietary Pulse Controlled Amplification (PCA) technology during a featured session at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo. The AACC Disruptive Technology Award recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high-quality testing.

 

GNA Biosolutions has demonstrated that PCA technology can detect dangerous pathogens within minutes in a variety of non-traditional laboratory settings such as field-hospitals, with the sensitivity and specificity of laboratory-based molecular diagnostics. GNA is currently developing an ultrafast (15 minutes or less), portable, low-cost integrated sample-to-result platform for infectious disease testing at the Point of Care (POC). The platform’s assay menu is currently planned to include Multidrug Resistant Tuberculosis (MDR-TB), Methicillin Resistant Staphylococcus Aureus (MRSA), and Multidrug-resistant Gram-negative bacteria (MDRGN).

 

The 70th AACC Annual Scientific Meeting is being held July 29-August 2 in Chicago, Illinois.